PMID- 30198974
OWN - NLM
STAT- MEDLINE
DCOM- 20181105
LR  - 20181105
IS  - 1473-5628 (Electronic)
IS  - 0143-3636 (Linking)
VI  - 39
IP  - 11
DP  - 2018 Nov
TI  - 18F-FDG-PET metabolic metrics and International Prognostic Score for risk 
      assessment in HIV-infected patients with Hodgkin lymphoma.
PG  - 1005-1012
LID - 10.1097/MNM.0000000000000905 [doi]
AB  - OBJECTIVES: Baseline metabolic metrics on fluorine-18-fluorodeoxyglucose PET 
      (F-FDG PET) have prognostic value in Hodgkin lymphoma. International Prognostic 
      Score (IPS) is used in the risk stratification of Hodgkin lymphoma. We compared 
      the metabolic indices in HIV-infected and the IPS in HIV-infected and uninfected 
      patients with Hodgkin lymphoma. PATIENTS AND METHODS: We retrospectively reviewed 
      the data of HIV-infected and HIV-uninfected patients with classic Hodgkin 
      lymphoma who had F-FDG PET for staging and compared the maximum standardized 
      uptake value, mean standardized uptake value, metabolic tumor volume, and total 
      lesion glycolysis between the two groups. We also compared the IPS and other 
      prognostic indicators and correlated them with the metabolic indices in the two 
      groups. RESULTS: We studied 160 patients, which included 57 patients who were 
      infected with HIV. The mean age was 33.84+/-11.88 years, with 38% (n=61) being 
      female. The median cluster of differentiation 4 count and HIV viral load were 
      259 cells/mm and 4837.50 copies/ml, respectively. No significant difference in 
      maximum standardized uptake value, mean standardized uptake value, metabolic 
      tumor volume, and total lesion glycolysis between the two groups was found. Among 
      the seven parameters of the IPS, only male sex (HIV-uninfected group higher, 
      P=0.005) and serum albumin less than 4 g/dl were significantly different. The 
      other parameters were not significantly different between the two groups. Other 
      prognostic indicators including bulky disease, extranodal involvement, and the 
      number of nodal groups involved were not significantly different between the two 
      groups. CONCLUSION: There was no significant difference in F-FDG metabolic 
      parameters, IPS, and other risk indicators between HIV-infected and 
      HIV-uninfected patients with Hodgkin lymphoma.
FAU - Lawal, Ismaheel O
AU  - Lawal IO
AD  - Department of Nuclear Medicine, Steve Biko Academic Hospital, University of 
      Pretoria, Pretoria.
FAU - Ankrah, Alfred O
AU  - Ankrah AO
AD  - Department of Nuclear Medicine, Steve Biko Academic Hospital, University of 
      Pretoria, Pretoria.
AD  - Department Nuclear Medicine and Molecular Imaging, University Medical Centre, 
      University of Groningen, Groningen, The Netherlands.
FAU - Popoola, Gbenga O
AU  - Popoola GO
AD  - Department of Epidemiology and Community Health, University of Ilorin, Ilorin, 
      Nigeria.
FAU - Nyakale, Nozipho E
AU  - Nyakale NE
AD  - Department of Nuclear Medicine, Inkosi Albert Lithuli Central Hospital, 
      University of Kwa-Zulu Natal, Durban, South Africa.
FAU - Boshomane, Tebatso G
AU  - Boshomane TG
AD  - Department of Nuclear Medicine, Steve Biko Academic Hospital, University of 
      Pretoria, Pretoria.
FAU - Reyneke, Florette
AU  - Reyneke F
AD  - Department of Nuclear Medicine, Steve Biko Academic Hospital, University of 
      Pretoria, Pretoria.
FAU - Lengana, Thabo
AU  - Lengana T
AD  - Department of Nuclear Medicine, Steve Biko Academic Hospital, University of 
      Pretoria, Pretoria.
FAU - Vorster, Mariza
AU  - Vorster M
AD  - Department of Nuclear Medicine, Steve Biko Academic Hospital, University of 
      Pretoria, Pretoria.
FAU - Sathekge, Mike M
AU  - Sathekge MM
AD  - Department of Nuclear Medicine, Steve Biko Academic Hospital, University of 
      Pretoria, Pretoria.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Nucl Med Commun
JT  - Nuclear medicine communications
JID - 8201017
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adult
MH  - Female
MH  - *Fluorodeoxyglucose F18
MH  - HIV/*physiology
MH  - Hodgkin Disease/*diagnostic imaging/metabolism/*virology
MH  - Humans
MH  - Male
MH  - *Positron-Emission Tomography
MH  - Prognosis
MH  - Risk Assessment
EDAT- 2018/09/11 06:00
MHDA- 2018/11/06 06:00
CRDT- 2018/09/11 06:00
PHST- 2018/09/11 06:00 [pubmed]
PHST- 2018/11/06 06:00 [medline]
PHST- 2018/09/11 06:00 [entrez]
AID - 10.1097/MNM.0000000000000905 [doi]
PST - ppublish
SO  - Nucl Med Commun. 2018 Nov;39(11):1005-1012. doi: 10.1097/MNM.0000000000000905.